Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Finished Goods (2017 - 2024)

Historic Finished Goods for RedHill Biopharma (RDHL) over the last 8 years, with Q4 2024 value amounting to $2.8 million.

  • RedHill Biopharma's Finished Goods fell 1496.39% to $2.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year decrease of 1496.39%. This contributed to the annual value of $2.8 million for FY2024, which is 1496.39% down from last year.
  • Latest data reveals that RedHill Biopharma reported Finished Goods of $2.8 million as of Q4 2024, which was down 1496.39% from $3.3 million recorded in Q4 2023.
  • RedHill Biopharma's Finished Goods' 5-year high stood at $6.8 million during Q4 2022, with a 5-year trough of $2.8 million in Q4 2024.
  • For the 5-year period, RedHill Biopharma's Finished Goods averaged around $4.9 million, with its median value being $4.7 million (2020).
  • As far as peak fluctuations go, RedHill Biopharma's Finished Goods surged by 152123.29% in 2020, and later tumbled by 5125.24% in 2023.
  • Over the past 5 years, RedHill Biopharma's Finished Goods (Quarter) stood at $4.7 million in 2020, then surged by 39.48% to $6.6 million in 2021, then increased by 3.39% to $6.8 million in 2022, then plummeted by 51.25% to $3.3 million in 2023, then dropped by 14.96% to $2.8 million in 2024.
  • Its Finished Goods stands at $2.8 million for Q4 2024, versus $3.3 million for Q4 2023 and $6.8 million for Q4 2022.